Unknown PHASE3 INTERVENTIONAL 3-arm NCT01229566

Efficacy Study to Treat Subjects With Severe Hypertriglyceridemia

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase III Study to Assess Efficacy and Safety of AKR-963 Therapy in Subjects With Severe Hypertriglyceridemia

Sponsor: Trygg Pharma, Inc.

Conditions Severe Hypertriglyceridemia

Interventions AKR-963

Updated 6 times since 2017 Last updated: Nov 23, 2011 Started: Oct 31, 2010 Primary completion: Jul 31, 2012 Completion: Jul 31, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Severe Hypertriglyceridemia, this trial is ongoing. The trial is conducted by Trygg Pharma, Inc. and has accumulated 6 data snapshots since 2010. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE3
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE3

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE3
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE3
Feb 2017 — Jun 2018 [monthly]

Unknown Status PHASE3

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Unknown Status PHASE3

First recorded

Oct 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Trygg Pharma, Inc.

Data source: Trygg Pharma, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Chicago, United States